Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility of wide-area transepithelial sampling with 3-dimensional computer-assisted analysis as an adjunct to forceps biopsy sampling in the surveillance of patients with Barrett's esophagus after endoscopic eradication therapy.

iGIE : innovation, investigation and insights·2026
Same author

Prospective cohort study of palliative treatment of esophageal cancer with liquid nitrogen spray cryotherapy.

Gastrointestinal endoscopy·2026
Same author

The Utility of Mucin 2 and Caudal-Type Homeobox Transcription Factor 2 Expression in the Diagnosis of Barrett's Esophagus: A Community-Based Study of Wide-Area Transepithelial Sampling and Forceps Biopsies.

The American journal of gastroenterology·2026
Same author

Adjunctive Use of Wide-Area Transepithelial Sampling-3D in Patients With Symptomatic Gastroesophageal Reflux Increases Detection of Barrett's Esophagus and Dysplasia.

The American journal of gastroenterology·2024
Same author

Artificial intelligence-enhanced volumetric laser endomicroscopy improves dysplasia detection in Barrett's esophagus in a randomized cross-over study.

Scientific reports·2022
Same author

Cryoballoon and Cryospray Ablation Therapies are Equivalent for Eradication of Barrett's Esophagus.

Techniques and innovations in gastrointestinal endoscopy·2022
Same journal

LOCAL RECURRENCE AFTER COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION: A LARGE INTERNATIONAL WESTERN MULTICENTER STUDY.

Gastrointestinal endoscopy·2026
Same journal

SINGLE-BLINDED RANDOMIZED CONTROLLED TRIAL COMPARING THE EFFECT OF UNDERWATER VERSUS CARBON DIOXIDE INSUFFLATION DURING PERORAL ENDOSCOPIC MYOTOMY ON POST-PROCEDURAL PAIN (U-POEM TRIAL).

Gastrointestinal endoscopy·2026
Same journal

Adverse events associated with endoscopic retrograde cholangiopancreatography (ERCP) and ERCP-related procedures.

Gastrointestinal endoscopy·2026
Same journal

Quality measures in the design, conduct, and reporting of endoscopic research.

Gastrointestinal endoscopy·2026
Same journal

Location of GI lesions with bleeding potential in patients with iron deficiency anemia: a multicenter prospective study.

Gastrointestinal endoscopy·2026
Same journal

TEMPORARY REMOVAL: Sustainability indicators for gastrointestinal endoscopy: a framework proposed by the Canadian Association of Gastroenterology and the American Society for Gastrointestinal Endoscopy.

Gastrointestinal endoscopy·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Fluorescent End-Labeling and Encapsulation of Long RNAs for Single-Molecule FRET-TIRF Microscopy
10:59

Fluorescent End-Labeling and Encapsulation of Long RNAs for Single-Molecule FRET-TIRF Microscopy

Published on: October 18, 2024

Prolonged endoclip retention time

Ariy Volfson, Matthew J McKinley

    Gastrointestinal Endoscopy
    |August 30, 2011
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Patch-Clamp Techniques for Single Endolysosomal Vesicle Analysis
    05:47

    Patch-Clamp Techniques for Single Endolysosomal Vesicle Analysis

    Published on: April 4, 2025

    Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
    06:10

    Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

    Published on: March 30, 2020

    Related Experiment Videos

    Last Updated: May 29, 2026

    Fluorescent End-Labeling and Encapsulation of Long RNAs for Single-Molecule FRET-TIRF Microscopy
    10:59

    Fluorescent End-Labeling and Encapsulation of Long RNAs for Single-Molecule FRET-TIRF Microscopy

    Published on: October 18, 2024

    Patch-Clamp Techniques for Single Endolysosomal Vesicle Analysis
    05:47

    Patch-Clamp Techniques for Single Endolysosomal Vesicle Analysis

    Published on: April 4, 2025

    Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
    06:10

    Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

    Published on: March 30, 2020